跳至主要内容
临床试验/NCT04812106
NCT04812106终止不适用

Long Chain Fatty Acid Oxidation Disorders (LC-FAOD) Online Disease Monitoring Program (DMP)

Ultragenyx Pharmaceutical Inc1 个研究点 分布在 1 个国家目标入组 8 人开始时间: 2022年7月25日最近更新:
适应症

试验速览

阶段
不适用
状态
终止
入组人数
8
试验地点
1
主要终点
Participant Survey: Disease Symptoms

研究概览

简要总结

The objectives of this study are to characterize the disease impact, the disease management and resource utilization, and provide benefits to the LC-FAOD community, by use of a convenient online platform for participants (or caregivers) to self-report information.

详细描述

The online LC-FAOD DMP is a non-interventional, prospective, observational disease-monitoring program conducted through a mobile/web-based application developed by the Sponsor. Participant data will be captured via the mobile/web-based application and entered into the database designed and maintained by the Sponsor and/or its designee. Additional objectives of the study are to benefit the LC-FAOD community by developing a comprehensive database for use by the LC-FAOD community to characterize patient experience, inform disease management, and enable further research, utilize the digital platform to notify patients, caregivers, and relevant patient advocacy groups of research studies and clinical trials and share aggregated and de-identified outputs to facilitate the exchange of information with patients and/or caregivers.

Participants can be on any treatment in order to participate. Medical management of the disease should continue as directed by the patient's physician(s). Specifically, no treatments, investigational agents, or experimental interventions will be provided as part of this online LC-FAOD DMP.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Diagnosis of LC-FAOD including: carnitine palmitoyltransferase (CPT I or CPT II) deficiency, very long chain acyl-CoA dehydrogenase (VLCAD) deficiency, long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency, trifunctional protein (TFP) deficiency, or carnitine-acylcarnitine translocase (CACT) deficiency.
  • Willing and able to provide consent or, if a minor, provide assent and informed consent by their legally authorized representative.
  • Access to the internet and an internet-enabled device.
  • Reside in the geographical regions where the platform is supported and approved by applicable IRB/IEC and /or health authority.
  • Not receiving triheptanoin through an Ultragenyx-sponsored interventional clinical trial or Ultragenyx Investigator Sponsored Trial (IST). NOTE: Individuals are eligible to participate in this online DMP if they previously participated in UX007 clinical trials, are currently participating in the in clinic UX007-CL401 (NCT04632953), are receiving triheptanoin through Expanded Access or Compassionate Use programs, or are receiving commercially available triheptanoin via prescription.

排除标准

  • 未提供

结局指标

主要结局

Participant Survey: Disease Symptoms

时间窗: 10 years

Patient Reported Outcomes: Infant and Toddler Quality of Life Questionnaire (ITQOL) Short Form

时间窗: 10 years

Patient Reported Outcomes: Medical Outcomes Study 12-Item Short Form Version 2 (SF-12v2) for Adults

时间窗: 10 years

Participant Survey: Patient and Caregiver-Reported Outcomes

时间窗: 10 years

LC-FAOD MCEs: Annualized Event Days in the Emergency Department (ED)/Hospital for all MCEs

时间窗: 10 years

LC-FAOD MCEs: Time to First MCE in all Newborn Patients (<=1 Year)

时间窗: 10 years

Disease Management as Assessed by Physical Activity

时间窗: 10 years

LC-FAOD Management: Nutrition and Dosing Utilized to Control LC-FAOD

时间窗: 10 years

LC-FAOD At-home Interventions: Types of Interventions Used

时间窗: 10 years

Interventions used to prevent or mitigate Major Clinical Events (MCEs)

LC-FAOD MCEs: Annualized Event Rate of all MCEs

时间窗: 10 years

MCEs include skeletal myopathy (rhabdomyolysis), hepatic (hypoglycemia, liver dysfunction), and cardiac disease (cardiomyopathy) events. An MCE is defined as any visit to the ED/acute care, hospitalization, emergency intervention (ie, any unscheduled administration of therapeutics in the clinic), or any similar event whether caused primarily by LC-FAOD or by an intercurrent illness complicated by LC-FAOD

Patient Reported Outcomes: Short-Form 10 (SF-10) Health Survey for Children

时间窗: 10 years

Participant Survey: Schooling and Work Status

时间窗: 10 years

Participant Survey: EuroQol Group 5-dimension 5-level (EQ-5D-5L) Instrument

时间窗: 10 years

Healthcare Resource Utilization: LC-FAOD-related Medical Resource Use Over Time

时间窗: 10 years

Participant Survey: Absenteeism/Presenteeism

时间窗: 10 years

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验